Pfizer projects up to $15B sales potential from mRNA vaccines in 2030

Dec. 12, 2022 2:25 PM ETPfizer Inc. (PFE)MRNA, BNTX, CVACBy: Dulan Lokuwithana, SA News Editor47 Comments

Pfizer Canada head office in Kirkland, Quebec, Canada.


  • Pfizer (NYSE:PFE) announced Monday that its messenger-RNA-based vaccine franchise led by the blockbuster COVID-19 shot Comirnaty will generate $10B – $15B commercial market opportunity by 2030.
  • In addition to Comirnaty, Pfizer’s (PFE) mRNA vaccine portfolio comprises multiple

Recommended For You

Comments (47)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.